Directional Asset Management Makes New $2.41 Million Investment in Amgen Inc. $AMGN

Key Points

• Directional Asset Management bought 7,361 shares of Amgen (NASDAQ:AMGN) in Q4, a new stake valued at about $2.41 million that represents roughly 2.1% of the fund’s portfolio and is its 12th-largest holding.
• Amgen beat Q4 estimates with $5.29 EPS and $9.87 billion revenue, set FY2026 guidance of 21.600–23.000 EPS, and declared a quarterly dividend of $2.52 (annualized $10.08, ~2.9% yield).
• Analyst sentiment is mixed—MarketBeat shows a consensus "Hold" (avg. target ~$356.62)—and near-term risks include previews of a Q1 earnings decline and roughly $4.1M of insider selling.

Directional Asset Management acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 7,361 shares of the medical research company's stock, valued at approximately $2,409,000. Amgen accounts for approximately 2.1% of Directional Asset Management's portfolio, making the stock its 12th largest position.

Other large investors also recently made changes to their positions in the company. Board of the Pension Protection Fund bought a new stake in Amgen in the 4th quarter valued at $26,000. Olistico Wealth LLC bought a new position in Amgen during the 4th quarter worth $33,000. Cloud Capital Management LLC bought a new position in Amgen during the 3rd quarter worth $34,000. Saranac Partners Ltd acquired a new stake in shares of Amgen during the third quarter worth $37,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth $37,000. Institutional investors own 76.50% of the company's stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Amgen Stock Up 0.8%

AMGN stock opened at $348.62 on Friday. The company has a market cap of $188.14 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 3.62 and a beta of 0.47. The business has a 50-day simple moving average of $361.24 and a 200 day simple moving average of $338.80. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the prior year, the company posted $5.31 earnings per share. The business's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.18 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen's dividend payout ratio (DPR) is currently 70.84%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. Royal Bank Of Canada upped their price target on shares of Amgen from $360.00 to $370.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Daiwa Securities Group lifted their price objective on shares of Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 10th. Canaccord Genuity Group assumed coverage on shares of Amgen in a report on Monday. They issued a "hold" rating and a $366.00 price objective for the company. Sanford C. Bernstein lowered shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 target price on the stock. in a research report on Tuesday, January 20th. Finally, Barclays assumed coverage on shares of Amgen in a report on Friday, February 20th. They set an "equal weight" rating and a $350.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $356.62.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.